Inframammary vs periareolar breast augmentation evidence is not a contest between a “best” incision and a “worst” one. It is evidence about where the surgeon enters the breast, which tissues are crossed, how the scar is placed, how the implant can be handled, and which patient priorities may matter most. The inframammary route follows the crease beneath the breast; the periareolar route follows the lower border of the areola. Both are established approaches for primary aesthetic augmentation, and neither guarantees an invisible scar, preserved sensation, uncomplicated breastfeeding or a particular final shape.
This review examines the history and current evidence for these two access routes in primary cosmetic breast augmentation. It focuses on access, scar outcomes, possible bacterial contamination, capsular contracture, breastfeeding questions and patient-specific trade-offs. The literature is mainly observational, and incision choice is often linked to implant pocket, implant type, breast anatomy and surgeon preference. The most defensible conclusion is therefore individual: the route should provide the access needed for the planned operation while respecting the patient’s tissues, future plans and tolerance for uncertainty.
How the two incision routes developed
Breast augmentation techniques evolved alongside the devices being placed. Early implant surgery had to balance the size and stiffness of the prosthesis with the need to create a pocket accurately. As implants, surgical instruments and pocket concepts changed, surgeons described several routes, including inframammary, periareolar, transaxillary and, historically, transumbilical access. The inframammary fold became a common route for aesthetic augmentation because it provides a direct line to the lower breast and allows the pocket to be seen and controlled. The periareolar route developed as a shorter, more concealed breast incision and can be useful when the areolar border, fold position or a limited lift also needs attention. Historical reviews describe this as an evolution of surgical access rather than proof that one route is universally superior.
Today, “incision choice” is only one variable. The implant plane may be subglandular, subpectoral, subfascial or dual-plane; the device may be silicone or saline; the breast may be small, tubular, asymmetrical, lax or previously operated on. A study that compares incisions without accounting for those factors can make a route appear responsible for an outcome that is partly explained by patient selection or the rest of the operation.
What an inframammary incision offers
An inframammary incision is placed in or near the natural crease beneath the breast. It generally gives the surgeon a direct, low-angle entry to the planned implant pocket. The route can avoid cutting through the central breast gland and the main nipple ducts, which is one reason it is often considered when future lactation or minimal glandular dissection is a priority. It also offers a familiar working angle for shaping the lower pole, checking pocket dimensions and controlling the position of the inframammary fold.
Direct access can be valuable when the surgeon needs to measure or adjust the pocket precisely, manage a relatively firm chest wall, place a larger implant through a controlled opening or correct a pre-existing fold asymmetry. It does not remove the need for careful tissue handling: the surgeon still works close to the fold, skin envelope and chest wall, and the incision may need to be positioned according to the planned implant dimensions rather than the fold visible before surgery.
The principal aesthetic compromise is the scar’s location. An inframammary scar may be hidden by the breast when the patient is standing and wearing ordinary clothing, but it can be visible when lying down, wearing a low garment or when the breast changes with ageing, pregnancy or weight. If the fold moves, the scar can become relatively high, low or more exposed. A well-placed incision and careful closure can improve the result, but scar biology is also influenced by genetics, skin pigmentation, wound tension, smoking, infection and postoperative healing.
What a periareolar incision offers
A periareolar incision follows part of the border between the darker areola and surrounding breast skin, most commonly along the lower semicircle. The colour transition can make a healed scar less conspicuous in some patients. The route can also be helpful when the areola is sufficiently large for the planned access, when the surgeon needs to adjust the relationship between the nipple–areola complex and the breast mound, or when a limited periareolar lift is part of a broader plan.
Its limits are just as important. The areola has a finite diameter, the opening may be shorter or less flexible for a particular implant, and the route may pass through breast tissue or ducts before the pocket is reached. Periareolar access can also affect nipple sensation because nerves near the nipple–areola complex are exposed to incision, traction, dissection and healing. A small lower-areolar incision is not the same as completely detaching the nipple and areola, and the effect on ducts, nerves and sensation depends on the exact operation rather than the word “periareolar” alone.
For patients with a small areola, thin tissue, a large implant request or a need for extensive lower-pole control, a surgeon may consider the access less forgiving. That is not a prohibition. It is a planning question: will the incision allow the device to be inserted without excessive force, will the pocket be fully controlled, and is the scar advantage worth the tissue that may be crossed?
Scar evidence: concealment is not the same as scar quality
Patients often expect the periareolar border to “hide” a scar and the inframammary fold to conceal one. Both descriptions can be true in one patient and misleading in another. A scar has several dimensions: colour, width, thickness, texture, symptoms, visibility in different positions and psychological impact. Incision length alone does not measure the whole outcome.
A 2024 case-series study used the validated SCAR-Q in patients who underwent primary augmentation through an inferior hemi-periareolar or inframammary-fold incision. At one and six months, patients in both groups generally reported little scar impact. The inframammary group had a lower psychosocial impact score, while the study found no statistically significant difference in scar appearance or scar-related symptoms between the groups. The authors rated the evidence as level IV. This is useful patient-reported evidence, but it is not a randomized comparison and it does not show that every inframammary scar looks better.
Other scar studies have examined inframammary access against axillary access rather than periareolar access. They suggest that early differences in scar height or vascularity may narrow by around a year, and that patient satisfaction can be high with more than one route. Those findings reinforce a broader point: scars mature, and a short-term photograph is not a reliable forecast of an individual scar at one year.
For a patient who values a scar within the areolar colour boundary, periareolar access may be attractive if the anatomy and planned implant permit it. For a patient who wants to minimise breast-gland dissection, preserve a lower-breast scar in a stable fold and prioritise direct pocket control, inframammary access may be more attractive. The consultation should discuss how the scar may look in the patient’s own posture, skin tone and breast shape rather than promising that either site will disappear.
Contamination, ducts and capsular contracture
The most discussed scientific concern about periareolar access is bacterial contamination. The nipple–areola complex and ducts contain the patient’s normal breast microbiome. When a periareolar route crosses glandular tissue or ducts, bacteria may enter the implant pocket. A subclinical bacterial biofilm is one proposed contributor to chronic inflammation and capsular contracture, in which the scar capsule around an implant becomes unusually firm, tight or distorted. This is a biologically plausible hypothesis, but it should not be presented as a proven explanation for every contracture.
Some comparative studies have reported more capsular contracture after periareolar than inframammary augmentation. In a 2008 retrospective review, contracture occurred in 0.59% of the inframammary group and 9.5% of the periareolar group. The size of that difference attracted attention, but the study was from one practice and was not randomized. A 2018 meta-analysis of seven comparative studies found higher contracture odds with periareolar versus inframammary access (OR 1.91, 95% CI 1.06–3.43). Its authors also called for longer follow-up and higher-quality studies. The result supports discussing a possible association; it does not establish that the incision alone caused the difference.
Capsular contracture has multiple possible contributors, including implant surface and filler, pocket plane, bleeding or seroma, infection, tissue injury, radiation in reconstructive populations, smoking and follow-up duration. Periareolar cohorts may differ from inframammary cohorts in several of those variables. A patient having a periareolar incision is not destined to develop contracture, and a patient having an inframammary incision is not protected from it.
The infection evidence is even less definitive. A surgical evidence review noted that the nipple–areola complex can have a higher bacterial burden than other incision areas, but concluded that convincing evidence that incision site changes clinical infection rates was lacking. Infection is uncommon after primary cosmetic augmentation, which makes a large, adequately powered direct comparison difficult. Low event rates, different definitions and retrospective reporting can obscure a modest real effect.
Where no-touch measures fit
Because contamination is a concern, surgeons may use measures such as nipple shields, glove changes, pocket irrigation, implant funnels, minimal implant handling and careful haemostasis. These practices are intended to reduce contact between the implant and skin, ducts, blood or other sources of bacterial exposure. They are part of an operative protocol, not a substitute for choosing a suitable access route.
Reviews of intra-operative methods in aesthetic augmentation have found a large amount of low-quality evidence. Studies of antibiotic or antiseptic irrigation have produced mixed results, and systematic reviews have not found randomized evidence strong enough to define one universal solution or bundle. A funnel may reduce direct implant contact or help with a shorter opening, but “no touch” is an aspiration rather than a literal guarantee: the funnel, skin and instruments still interact. The patient should not be told that a device neutralises the possible contamination trade-off of a periareolar incision.
In practical terms, the relevant question is not whether one incision is sterile and the other is contaminated. It is whether the entire operation is planned and performed with appropriate skin preparation, tissue handling, implant handling, pocket management and infection surveillance. Incision route may be one risk-related variable among several.
Breastfeeding: what the evidence can and cannot promise
Breastfeeding is a common question for patients who may have children after augmentation. Milk production depends on functioning glandular tissue, ducts, nerves, hormones, breast development before surgery and effective milk removal after birth. An implant can sit below or above the pectoral muscle, and those choices may influence milk production independently of the incision. Pre-existing hypoplasia or tubular development can also limit supply, so a future difficulty should not automatically be attributed to the surgical scar.
Regulatory patient materials have historically described the periareolar site as more likely to be associated with breastfeeding difficulty and the inframammary site as generally less likely. Current CDC guidance similarly says that incisions around the areola are more likely to reduce milk production, while noting that most mothers with prior breast surgery can produce some milk and that full supply cannot be guaranteed. The CDC also notes that implants below the muscle usually affect milk production less than implants above the muscle. These are counselling points, not a prediction for one patient.
Comparative research is not perfectly consistent with a simple incision rule. A 2018 meta-analysis found that women with implants were less likely to establish exclusive breastfeeding than women without implants, but did not find evidence that a periareolar incision reduced exclusive breastfeeding compared with an inframammary incision (pooled RR 0.84, 95% CI 0.45–1.58). A 2016 cohort study reported breastfeeding at similar proportions for inframammary and periareolar groups, around 47% and 46%, respectively, with no significant difference by incision approach. A separate five-year follow-up analysis of more than 3,500 women who gave birth after primary augmentation reported that most were able to breastfeed and that lactation complications were comparable across incision type, implant size and pocket location.
These findings do not erase the anatomical concern. They show that breastfeeding outcomes are influenced by many factors and that available studies may be underpowered for a modest incision-specific effect. A patient who places a high value on preserving lactation should tell the surgeon before the operation, ask whether the planned route will cross glandular tissue or ducts, discuss implant plane and review the possibility of needing lactation support or supplementation. No incision can promise a full milk supply.
Patient-specific trade-offs
The choice between these routes is most useful when it is framed as a set of priorities:
- Need for pocket control: An inframammary route often gives direct access for fold positioning and lower-pole dissection. Periareolar access may be useful when the areola or nipple position is part of the correction.
- Breast and areola size: A small areola or a large, firm implant can limit the practicality of periareolar insertion. The surgeon should explain whether the device can be introduced without undue force or tissue trauma.
- Glandular dissection: Inframammary access may avoid crossing central breast tissue, whereas periareolar access may cross breast tissue or ducts. The exact dissection matters more than the label alone.
- Scar priorities: Periareolar scars may blend with a colour boundary; inframammary scars may sit in a fold and be hidden by the breast. Skin biology and future breast change can alter either result.
- Sensation: Nipple and skin sensation can change after augmentation through either route. Periareolar surgery deserves a specific discussion because the nipple–areola complex is close to the incision and dissection.
- Future pregnancy and breastfeeding: The patient’s reproductive plans, baseline glandular tissue and implant plane should be considered together with the incision. Breast growth and stretching after pregnancy can change shape and scars regardless of access.
- Asymmetry, tuberous shape or a planned lift: When the operation includes reshaping rather than implant placement alone, the access route may be selected to solve the anatomical problem, not simply to minimise one scar.
The right consultation question is therefore not “Which incision is invisible?” It is “Which access route gives the surgeon adequate control for my anatomy, while best respecting the outcomes I value?” A written plan should identify the likely incision, implant plane, device dimensions, alternatives if the anatomy differs from photographs and the possibility that the final decision may be adjusted in the operating room for safety.
Limitations of the evidence
This is a narrative evidence review, not a systematic review conducted specifically for this page and not an individual surgical recommendation. Direct comparisons of inframammary and periareolar access are mostly retrospective or prospective non-randomized cohorts. Patients are not assigned an incision at random: anatomy, areola size, implant choice, pocket, previous surgery, surgeon experience and aesthetic preference influence the route.
Capsular contracture is not the same endpoint as infection, and neither endpoint is the same as scar satisfaction or breastfeeding success. Studies use different definitions, follow-up periods and devices. Breastfeeding research is affected by baseline fertility, prior pregnancies, hypoplasia, implant plane, smoking, infant factors and whether “success” means any breastfeeding, mixed feeding or exclusive breastfeeding. The reported scar studies are often small and may not represent every skin type or patient population. For these reasons, pooled estimates should guide questions and consent, not act as a personal probability.
Conclusion
The current inframammary vs periareolar breast augmentation evidence supports a balanced discussion. Inframammary access usually offers direct pocket and fold control and may reduce the need to cut through central breast tissue. Periareolar access can place the scar at a colour transition and may assist selected areolar or nipple-position corrections, but it can involve breast tissue or ducts and deserves a specific conversation about sensation, lactation and possible contracture association. Existing studies suggest higher capsular-contracture odds with periareolar access, yet the evidence is observational and multifactorial; clinical infection differences are not convincingly established.
For a patient, scar visibility, future breastfeeding, implant size, areola dimensions, tissue coverage, asymmetry, planned lift and surgeon access all belong in the same decision. Neither route is automatically safer, more concealed or more suitable for everyone. A qualified plastic surgeon should explain the anatomy-specific plan, the quality of the evidence and the uncertainties that remain before consent.
Frequently asked questions
Is an inframammary incision safer than a periareolar incision?
Neither is universally safer. Comparative studies suggest that periareolar access may be associated with higher capsular-contracture rates, but the evidence is mostly observational and contracture has multiple causes. Clinical infection differences by incision site have not been convincingly demonstrated.
Which incision leaves the least visible scar?
It depends on the patient’s areola, fold, skin tone, scar biology, posture and how the breast changes over time. A periareolar scar may blend with the areolar border, while an inframammary scar may be hidden in the fold. Neither should be promised to disappear.
Does a periareolar incision cause capsular contracture?
No. It may be associated with a higher rate in some comparative studies, possibly because glandular or ductal bacteria can enter the pocket, but this mechanism is not proven for every case. Implant, pocket, bleeding, infection and patient factors also matter.
Can I breastfeed after an inframammary or periareolar augmentation?
Many women can breastfeed after augmentation, but a full milk supply cannot be guaranteed. Around-areola incisions may be more likely to reduce milk production, while implant position below the muscle often affects production less than above-muscle placement. Baseline breast development and other factors are important.
Does inframammary access preserve nipple sensation?
It may avoid some direct dissection around the nipple–areola complex, but sensation can change after either incision because nerves are affected by surgery, swelling, scar and tissue tension. The exact technique and individual healing determine the outcome.
Why might a surgeon recommend periareolar access?
The route may be useful when the areola is large enough for the planned device, when the nipple–areola position needs adjustment, or when a selected periareolar lift is part of the plan. The recommendation should also address the potential trade-offs involving ducts, sensation, scar and access.
Can a surgeon change the planned incision during surgery?
The expected route should be discussed and documented before consent, including reasonable alternatives. If anatomy, implant dimensions or tissue safety differ from the preoperative plan, the surgeon may need to adjust the approach within the consented options. Ask how such decisions are handled before surgery.
Related reading
For plain-language procedural context, see our breast augmentation operation guide. For the relationship between implant plane and tissue coverage, read the evidence review of breast implant pocket placement and the review of dual-plane augmentation evidence. For planning tools and anatomy-specific communication, see the evidence review of 3D imaging and implant planning. Patients asking about contracture can also read the practical guide to capsular contracture after breast augmentation.